Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday [Seeking Alpha]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Seeking Alpha
Rezdiffra's rapid commercialization and first-mover advantage in the MASH market underpin robust sales growth, with Q3 net sales at $287.3M and 29,500 active patients. Geographic expansion in Europe, pipeline catalysts (F4 trial), and under-diagnosis of MASH provide a long growth runway and potential for upside surprises. Concerns over GLP-1 competition are overblown; Rezdiffra shows high patient retention and potential synergy with GLP-1s, supporting continued market penetration. magicmine/iStock via Getty Images Last year , I initiated Madrigal Pharmaceuticals, Inc. ( MDGL ) as a Strong Buy due to the blockbuster pace of commercialization for Rezdiffra following FDA approval in March 2024. Since then, the stock has appreciated from $293 to $465, a robust gain of 58% outpacing This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of MDGL either through stock ownership, options, or other derivatives. I wrote this article myse
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPR Newswire
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPR Newswire
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPR Newswire
MDGL
Earnings
- 11/4/25 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website